Allogeneic Stem Cell Transplantation with BEAM and Alemtuzumab Conditioning Immediately after Remission Induction Has Curative Potential in Advanced T-Cell Non-Hodgkin's Lymphoma

详细信息    查看全文

• 作者：Anna Czajczynska ; Andreas G眉nther ; Rol ; Repp ; Andreas Humpe ; Natalie Schub ; Thorsten Raff ; Maike Nickelsen ; Andr茅 Schrauder ; Martin Schrappe ; Michael Kneba ; Martin Gramatzki
• 关键词：Advanced T cell NHL ; Allogeneic stem cell transplantation ; BEAM ; Alemtuzumab ; Reduced-intensity conditioning
• 刊名：Biology of Blood and Marrow Transplantation
• 出版年：November, 2013
• 年：2013
• 卷：19
• 期：11
• 页码：1632-1637
• 全文大小：290 K

文摘

Patients with relapsed or refractory advanced T cell non-Hodgkin lymphoma have a dismal prognosis and may not even reach allogeneic hematopoietic stem cell transplantation (HSCT) in adequate condition. We present the outcome of 24 consecutive patients (age range 11 to 65聽years) treated at a single institution in Kiel within a recent 5.5-year time frame with allogeneic HSCT in a rather uniform approach. Relapsed and refractory T and natural killer cell lymphomas of various subtypes were included. All patients except 1 were in progression or relapse before start of pretransplantation salvage therapy. Five patients had relapsed after autologous HSCT. With intensive remission induction therapy, usually the CLAEG (cladribine, cytosine arabinoside, and etoposide with granulocyte colony-stimulating factor support) protocol, attempts were made to improve disease control and proceed immediately to conditioning with carmustine, etoposide, cytosine arabinoside, melphalan (BEAM), and medium-dose alemtuzumab. Twenty of 21 patients who received CLAEG induction therapy benefited from this protocol and 1 patient appeared to be therapy-resistant. At the time of allogeneic HSCT, 9 patients were in complete remission (CR) (2 in CR1, 5 in CR2, and 2 in CR聽>2), whereas 50% had never achieved CR. Nineteen transplants were obtained from matched or partially matched unrelated donors and only 5 from siblings. With a median follow-up of 321聽days (1252聽days for surviving patients), 20 of 22聽assessable patients reached CR. Five of these patients had hematologic or molecular relapse. With donor lymphocyte infusions, 1 patient became minimal residual disease MRD negative again and has maintained CR for more than 4聽years. The frequency of grades II to IV acute graft-versus-host disease was 25% and chronic graft-versus-host disease, 30%. Intense reinduction therapy followed by reduced-intensity BEAM-alemtuzumab conditioning and allogeneic HSCT is effective and offers curative potential for patients with advanced T cell lymphomas, even for those not in remission.